Open AccessModest doses of β-glucan do not reduce concentrations of potentially atherogenic lipoproteins
Author(s) -
Julie A. Lovegrove,
Anna M. Clohessy,
Hubert Milon,
Christine M Williams
Publication year - 2000
Publication title -
american journal of clinical nutrition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.608
H-Index - 336
eISSN - 1938-3207
pISSN - 0002-9165
DOI - 10.1093/ajcn/72.1.49
Subject(s) - postprandial , bran , cholesterol , insulin , chemistry , beta glucan , medicine , glucan , hyperlipidemia , placebo , food science , endocrinology , diabetes mellitus , biochemistry , raw material , alternative medicine , organic chemistry , pathology
In 1997, the US Food and Drug Administration passed a unique ruling that allowed oat bran to be registered as the first cholesterol-reducing food at a dosage of 3 g beta-glucan/d.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom